Prime Medicine Inc
PRME4.379USD
+0.339+8.39%
交易中 （美東）報價延遲15分鐘
574.33M總市值
虧損本益比TTM
關於 Prime Medicine Inc 公司
Prime Medicine, Inc. 是一家生物技術公司，致力於爲患者創造和提供基因編輯療法。該公司部署了其基因編輯技術 Prime Editing 平臺，以開發一類新型差異化、一次性基因療法。該公司致力於開發 Prime Editors，作爲一種具有變革潛力的新型療法，以擴大治療性精準基因藥物的應用。該公司已建立了一個多元化的試驗性治療項目組合，這些項目圍繞核心重點領域組織，即血液學和免疫學、肝臟、肺、眼部和神經肌肉。其其他重點領域的項目處於臨牀前開發的早期階段，包括肝臟項目，如威爾遜氏病和糖原累積症 1b；肺項目，如囊性纖維化；眼部項目，如視紫紅質突變引起的視網膜色素變性，以及神經肌肉項目，包括弗裏德賴希共濟失調和 1 型肌強直營養不良症。
公司簡介
公司代碼PRME
公司名稱Prime Medicine Inc
上市日期Oct 20, 2022
CEODr. Allan Reine, M.D.
員工數量214
證券類型Ordinary Share
年結日Oct 20
公司地址60 First St.
城市CAMBRIDGE
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02141
電話16174650013
網址https://primemedicine.com/
公司代碼PRME
上市日期Oct 20, 2022
CEODr. Allan Reine, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Allan Reine, M.D.
Dr. Allan Reine, M.D.
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
125.00K
--
Dr. Ann Louise Lee, Ph.D.
Dr. Ann Louise Lee, Ph.D.
Chief Technical Officer
Chief Technical Officer
100.00K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Chief Business Officer
Chief Business Officer
20.00K
--
Mr. Robert Taylor (Bob) Nelsen
Mr. Robert Taylor (Bob) Nelsen
Independent Director
Independent Director
16.08K
--
Dr. Meredith Goldwasser
Dr. Meredith Goldwasser
Senior Vice President - Strategy and Corporate Operations
Senior Vice President - Strategy and Corporate Operations
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Independent Director
Independent Director
--
--
Ms. Hannah Deresiewicz
Ms. Hannah Deresiewicz
Investor Relations
Investor Relations
--
--
Dr. Andrew Anzalone, M.D., Ph.D.
Dr. Andrew Anzalone, M.D., Ph.D.
Co-Founder, Head of Prime Editing Platform
Co-Founder, Head of Prime Editing Platform
--
--
Dr. Thomas J. Cahill, M.D., Ph.D.
Dr. Thomas J. Cahill, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. David Schenkein, M.D.
Dr. David Schenkein, M.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Allan Reine, M.D.
Dr. Allan Reine, M.D.
Chief Executive Officer, Chief Financial Officer, Director
Chief Executive Officer, Chief Financial Officer, Director
125.00K
--
Dr. Ann Louise Lee, Ph.D.
Dr. Ann Louise Lee, Ph.D.
Chief Technical Officer
Chief Technical Officer
100.00K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Chief Business Officer
Chief Business Officer
20.00K
--
Mr. Robert Taylor (Bob) Nelsen
Mr. Robert Taylor (Bob) Nelsen
Independent Director
Independent Director
16.08K
--
Dr. Meredith Goldwasser
Dr. Meredith Goldwasser
Senior Vice President - Strategy and Corporate Operations
Senior Vice President - Strategy and Corporate Operations
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Independent Director
Independent Director
--
--
收入明細
FY2025Q1
FY2024
FY2022
暫無數據
地區USD
名稱
營收
佔比
United States
1.45M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月10日 週六
更新時間: 5月10日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Liu (David R)
11.97%
ARCH Venture Partners
9.14%
Alphabet, Inc.
8.90%
Newpath Partners LP
3.61%
Gottesdiener (Keith Michael)
2.58%
Other
63.81%
持股股東
持股股東
佔比
Liu (David R)
11.97%
ARCH Venture Partners
9.14%
Alphabet, Inc.
8.90%
Newpath Partners LP
3.61%
Gottesdiener (Keith Michael)
2.58%
Other
63.81%
股東類型
持股股東
佔比
Venture Capital
22.99%
Investment Advisor
19.66%
Individual Investor
19.20%
Investment Advisor/Hedge Fund
8.25%
Corporation
4.54%
Hedge Fund
3.95%
Research Firm
0.51%
Family Office
0.05%
Bank and Trust
0.04%
Other
20.81%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
270
104.38M
77.61%
-19.33M
2025Q1
282
106.20M
80.90%
-20.25M
2024Q4
272
108.78M
82.93%
-18.95M
2024Q3
253
113.13M
92.43%
-10.21M
2024Q2
247
124.37M
103.99%
+15.29M
2024Q1
226
122.24M
102.62%
+28.30M
2023Q4
206
100.04M
102.85%
+26.61M
2023Q3
169
100.64M
103.49%
+30.08M
2023Q2
156
87.82M
90.36%
+22.34M
2023Q1
141
87.13M
89.71%
+20.94M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Liu (David R)
20.24M
15.42%
+84.00K
+0.42%
Jun 30, 2025
ARCH Venture Partners
15.46M
11.77%
--
--
Nov 12, 2024
Alphabet, Inc.
15.06M
11.47%
--
--
Mar 31, 2025
Newpath Partners LP
6.11M
4.65%
--
--
Dec 31, 2024
Gottesdiener (Keith Michael)
4.36M
3.32%
+250.00K
+6.08%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
4.14M
3.16%
+165.27K
+4.15%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.93M
2.99%
-147.01K
-3.61%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.75M
2.85%
-54.79K
-1.44%
Mar 31, 2025
The Vanguard Group, Inc.
3.64M
2.77%
-13.97K
-0.38%
Mar 31, 2025
ARK Investment Management LLC
3.10M
2.36%
-2.06M
-39.90%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
ARK Genomic Revolution ETF
0.55%
Global X Genomics & Biotechnology ETF
0.4%
AXS Green Alpha ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
查看更多
ARK Genomic Revolution ETF
佔比0.55%
Global X Genomics & Biotechnology ETF
佔比0.4%
AXS Green Alpha ETF
佔比0.06%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
iShares Micro-Cap ETF
佔比0.03%
iShares Russell 2000 Value ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
